Quick Answer
GALECTIN THERAPEUTICS INC reported Earnings Per Share Diluted of $0.48 (loss) per share for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +36.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $0.10 (loss) per share | Q1 2021: $0.11 (loss) per share | Q2 2021: $0.15 (loss) per share | Q3 2021: $0.14 (loss) per share | Q1 2022: $0.17 (loss) per share | Q2 2022: $0.16 (loss) per share | Q3 2022: $0.14 (loss) per share | Q1 2023: $0.19 (loss) per share | Q2 2023: $0.15 (loss) per share | Q3 2023: $0.24 (loss) per share | Q1 2024: $0.19 (loss) per share | Q2 2024: $0.20 (loss) per share | Q3 2024: $0.18 (loss) per share | Q1 2025: $0.15 (loss) per share | Q2 2025: $0.12 (loss) per share | Q3 2025: $0.13 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), GALECTIN THERAPEUTICS INC's Earnings Per Share Diluted has declined by 17.1%.
- Historical annual values: Fiscal year 2025: $0.48 (loss) per share | Fiscal year 2024: $0.76 (loss) per share | Fiscal year 2023: $0.74 (loss) per share | Fiscal year 2022: $0.65 (loss) per share | Fiscal year 2021: $0.52 (loss) per share | Fiscal year 2020: $0.41 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: